ENGAGE-HF Mobile App for Heart Failure
(ENGAGE-HF Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it focuses on optimizing heart failure medications, so you may need to adjust your current heart failure treatments.
What data supports the effectiveness of the ENGAGE-HF Mobile Application treatment for heart failure?
Research shows that mobile health apps can improve the quality of life for heart failure patients by helping them manage their condition better, even though not all studies showed positive results for other outcomes. These apps assist patients in tracking important health indicators like blood pressure and weight, which can lead to better self-care.12345
Is the ENGAGE-HF Mobile App safe for use in humans?
How is the ENGAGE-HF Mobile App treatment different from other heart failure treatments?
The ENGAGE-HF Mobile App is unique because it uses mobile health technology to help patients with heart failure manage their symptoms and medication adherence through self-monitoring and education, which is different from traditional treatments that primarily focus on medication and lifestyle changes without the use of technology.3461011
What is the purpose of this trial?
The ENGAGE-HF mobile application tracks three key features over time: (1) heart failure health status, (2) vital signs (e.g., blood pressure, heart rate) and weight, and (3) the quality of heart failure medication therapy. Helping patients understand how these characteristics interact and change over time may improve their ability to understand and manage heart failure.In this study, the investigators aim to evaluate whether the ENGAGE-HF mobile application, by facilitating the behavior change strategies of self-monitoring and feedback, and a clinician-facing dashboard, improves the optimization of heart failure guideline-directed medical therapies (GDMT) and quality of life.An optional sub-study of cognitive function will invite all eligible participants enrolled in the main study to participate.
Research Team
Michael Dorsch, PharmD
Principal Investigator
University of Michigan
Eligibility Criteria
This trial is for heart failure patients recently hospitalized or discharged, with a left ventricular ejection fraction below 50%. Participants should not have started at least two recommended heart failure treatments, or be on less than half the target dose.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants use the ENGAGE-HF mobile application integrated with a remote blood pressure cuff and scale, along with a clinician-facing dashboard, to optimize heart failure management.
Cognitive Function Sub-study (optional)
Eligible participants are invited to participate in a sub-study assessing cognitive function using various neurocognitive assessments.
Follow-up
Participants are monitored for safety and effectiveness after the intervention, including assessments of medication optimization and quality of life.
Treatment Details
Interventions
- ENGAGE-HF Mobile Application
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Michigan
Lead Sponsor
Johns Hopkins University
Collaborator
Boston University
Collaborator
Stanford University
Collaborator